Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind Placebo-Controlled Study of the Activity of AVE1625 at Doses of 10 mg and 40mg for 12 Weeks in Patients With Mild to Moderate Alzheimer's Disease

NCT00380302 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00380302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00380302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind Placebo-Controlled Study of the Activity of AVE1625 at Doses of 10 mg and 40mg for 12 Weeks in Patients With Mild to Moderate Alzheimer's Disease
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2006
Completion date
July 31, 2007
Enrollment
162 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease